Roger Faroux

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Thierry Conroy, Pascal Hammel, Mohamed Hebbar et al. · New England Journal of Medicine · 2018 · 2.8K citations · Full text

Medicine, Oncology, Pharmacology +14

Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial

Christophe Louvet, Roberto Labianca, Pascal Hammel et al. · Journal of Clinical Oncology · 2005 · 954 citations · Full text

Medicine, Oncology, Pharmacology +12

Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study

Julien Edeline, M. Benabdelghani, Aurélie Bertaut et al. · Journal of Clinical Oncology · 2019 · 529 citations

Medicine, Oncology, Surgery +11

Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Thierry Conroy, Florence Castan, Anthony Lopez et al. · JAMA Oncology · 2022 · 324 citations · Full text

Medicine, Oncology, Surgery +14

Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial

Thierry André, Déwi Vernerey, Laurent Mineur et al. · Journal of Clinical Oncology · 2018 · 174 citations

Medicine, Oncology, Pharmacology +17